Is MOLN or CADL more profitable?

Candel Therapeutics' return on equity of -60.42% beat Molecular Partners' return on equity. Company Net Margins Return on Equity Return on Assets Molecular Partners N/A -66.62% -54.85% Candel Therapeutics N/A -60.42% -41.33%

Is CLYM or MOLN more profitable?

Climb Bio's return on equity of -31.45% beat Molecular Partners' return on equity. Company Net Margins Return on Equity Return on Assets Climb Bio N/A -31.45% -30.39% Molecular Partners N/A -66.62% -54.85%

Molecular Partners (MOLN) Competitors

$3.92 +0.04 (+1.03%)

Closing price 02:26 PM Eastern

Extended Trading

$3.80 -0.12 (-3.16%)

As of 04:06 PM Eastern

Compare

MOLN vs. ZVRA, CRMD, CADL, ACRS, and CLYM

Should you buy Molecular Partners stock or one of its competitors? MarketBeat compares Molecular Partners with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Molecular Partners include Zevra Therapeutics (ZVRA), CorMedix (CRMD), Candel Therapeutics (CADL), Aclaris Therapeutics (ACRS), and Climb Bio (CLYM). These companies are all part of the "pharmaceutical products" industry.

How does Molecular Partners compare to Zevra Therapeutics?

Zevra Therapeutics (NASDAQ:ZVRA) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

Zevra Therapeutics has higher revenue and earnings than Molecular Partners. Molecular Partners is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$106.47M	7.50	$83.23M	$1.99	6.78
Molecular Partners	$5.65M	28.02	-$74.41M	-$1.94	N/A

Zevra Therapeutics has a net margin of 101.58% compared to Molecular Partners' net margin of 0.00%. Zevra Therapeutics' return on equity of 51.49% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	101.58%	51.49%	28.86%
Molecular Partners	N/A	-66.62%	-54.85%

Zevra Therapeutics currently has a consensus target price of $29.29, suggesting a potential upside of 116.93%. Molecular Partners has a consensus target price of $8.38, suggesting a potential upside of 113.65%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Zevra Therapeutics is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 26.6% of Molecular Partners shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by insiders. Comparatively, 5.9% of Molecular Partners shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Zevra Therapeutics had 12 more articles in the media than Molecular Partners. MarketBeat recorded 14 mentions for Zevra Therapeutics and 2 mentions for Molecular Partners. Zevra Therapeutics' average media sentiment score of 0.47 beat Molecular Partners' score of 0.44 indicating that Zevra Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Zevra Therapeutics	Neutral
Molecular Partners	Neutral

Zevra Therapeutics has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market. Comparatively, Molecular Partners has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

Summary

Zevra Therapeutics beats Molecular Partners on 13 of the 16 factors compared between the two stocks.

How does Molecular Partners compare to CorMedix?

CorMedix (NASDAQ:CRMD) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

CorMedix has higher revenue and earnings than Molecular Partners. Molecular Partners is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	2.21	$163.05M	$2.13	4.12
Molecular Partners	$5.65M	28.02	-$74.41M	-$1.94	N/A

CorMedix has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market. Comparatively, Molecular Partners has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market.

CorMedix presently has a consensus price target of $15.00, suggesting a potential upside of 71.04%. Molecular Partners has a consensus price target of $8.38, suggesting a potential upside of 113.65%. Given Molecular Partners' higher possible upside, analysts clearly believe Molecular Partners is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

34.2% of CorMedix shares are held by institutional investors. Comparatively, 26.6% of Molecular Partners shares are held by institutional investors. 3.5% of CorMedix shares are held by company insiders. Comparatively, 5.9% of Molecular Partners shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

CorMedix has a net margin of 45.25% compared to Molecular Partners' net margin of 0.00%. CorMedix's return on equity of 45.57% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	45.25%	45.57%	24.76%
Molecular Partners	N/A	-66.62%	-54.85%

In the previous week, CorMedix had 1 more articles in the media than Molecular Partners. MarketBeat recorded 3 mentions for CorMedix and 2 mentions for Molecular Partners. CorMedix's average media sentiment score of 0.47 beat Molecular Partners' score of 0.44 indicating that CorMedix is being referred to more favorably in the media.

Company	Overall Sentiment
CorMedix	Neutral
Molecular Partners	Neutral

Summary

CorMedix beats Molecular Partners on 13 of the 16 factors compared between the two stocks.

How does Molecular Partners compare to Candel Therapeutics?

Molecular Partners (NASDAQ:MOLN) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

Candel Therapeutics has lower revenue, but higher earnings than Molecular Partners. Candel Therapeutics is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Molecular Partners	$5.65M	28.02	-$74.41M	-$1.94	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

Molecular Partners has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.49, suggesting that its stock price is 149% less volatile than the broader market.

Molecular Partners currently has a consensus target price of $8.38, indicating a potential upside of 113.65%. Candel Therapeutics has a consensus target price of $18.00, indicating a potential upside of 115.57%. Given Candel Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Candel Therapeutics is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

26.6% of Molecular Partners shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 5.9% of Molecular Partners shares are held by insiders. Comparatively, 14.3% of Candel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Candel Therapeutics' return on equity of -60.42% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Molecular Partners	N/A	-66.62%	-54.85%
Candel Therapeutics	N/A	-60.42%	-41.33%

In the previous week, Candel Therapeutics had 1 more articles in the media than Molecular Partners. MarketBeat recorded 3 mentions for Candel Therapeutics and 2 mentions for Molecular Partners. Candel Therapeutics' average media sentiment score of 0.60 beat Molecular Partners' score of 0.44 indicating that Candel Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Molecular Partners	Neutral
Candel Therapeutics	Positive

Summary

Candel Therapeutics beats Molecular Partners on 10 of the 14 factors compared between the two stocks.

How does Molecular Partners compare to Aclaris Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

Molecular Partners has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. Aclaris Therapeutics' return on equity of -55.89% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%
Molecular Partners	N/A	-66.62%	-54.85%

In the previous week, Aclaris Therapeutics had 12 more articles in the media than Molecular Partners. MarketBeat recorded 14 mentions for Aclaris Therapeutics and 2 mentions for Molecular Partners. Aclaris Therapeutics' average media sentiment score of 1.31 beat Molecular Partners' score of 0.44 indicating that Aclaris Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aclaris Therapeutics	Positive
Molecular Partners	Neutral

Aclaris Therapeutics has higher revenue and earnings than Molecular Partners. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	73.13	-$64.92M	-$0.56	N/A
Molecular Partners	$5.65M	28.02	-$74.41M	-$1.94	N/A

Aclaris Therapeutics presently has a consensus price target of $11.50, suggesting a potential upside of 180.49%. Molecular Partners has a consensus price target of $8.38, suggesting a potential upside of 113.65%. Given Aclaris Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Aclaris Therapeutics is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

98.3% of Aclaris Therapeutics shares are held by institutional investors. Comparatively, 26.6% of Molecular Partners shares are held by institutional investors. 4.8% of Aclaris Therapeutics shares are held by company insiders. Comparatively, 5.9% of Molecular Partners shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Aclaris Therapeutics has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Molecular Partners has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

Summary

Aclaris Therapeutics beats Molecular Partners on 13 of the 17 factors compared between the two stocks.

How does Molecular Partners compare to Climb Bio?

Climb Bio (NASDAQ:CLYM) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

69.8% of Climb Bio shares are owned by institutional investors. Comparatively, 26.6% of Molecular Partners shares are owned by institutional investors. 2.6% of Climb Bio shares are owned by insiders. Comparatively, 5.9% of Molecular Partners shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Climb Bio currently has a consensus price target of $21.64, indicating a potential upside of 100.34%. Molecular Partners has a consensus price target of $8.38, indicating a potential upside of 113.65%. Given Molecular Partners' higher possible upside, analysts clearly believe Molecular Partners is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Climb Bio's return on equity of -31.45% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-31.45%	-30.39%
Molecular Partners	N/A	-66.62%	-54.85%

Climb Bio has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market. Comparatively, Molecular Partners has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market.

In the previous week, Climb Bio had 5 more articles in the media than Molecular Partners. MarketBeat recorded 7 mentions for Climb Bio and 2 mentions for Molecular Partners. Climb Bio's average media sentiment score of 0.60 beat Molecular Partners' score of 0.44 indicating that Climb Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Climb Bio	Positive
Molecular Partners	Neutral

Climb Bio has higher earnings, but lower revenue than Molecular Partners. Climb Bio is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A
Molecular Partners	$5.65M	28.02	-$74.41M	-$1.94	N/A

Summary

Climb Bio beats Molecular Partners on 10 of the 15 factors compared between the two stocks.

Get Molecular Partners News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MOLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MOLN vs. The Competition

Export

Metric	Molecular Partners	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$156.65M	$3.34B	$6.50B	$11.95B
Dividend Yield	N/A	2.31%	2.67%	5.61%
P/E Ratio	-2.02	18.83	24.65	23.63
Price / Sales	28.02	290.84	500.87	105.21
Price / Cash	N/A	120.20	43.05	54.72
Price / Book	1.63	8.00	10.43	6.70
Net Income	-$74.41M	$23.89M	$3.56B	$337.26M
7 Day Performance	-2.73%	-3.49%	-1.39%	-1.41%
1 Month Performance	-5.27%	1.03%	0.86%	1.15%
1 Year Performance	3.29%	34.39%	19.42%	22.61%

Molecular Partners Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MOLN Molecular Partners	2.4649 of 5 stars	$3.92 +1.0%	$8.38 +113.6%	+2.1%	$156.65M	$5.65M	N/A	180	Short Interest Increase Gap Down
ZVRA Zevra Therapeutics	4.5116 of 5 stars	$10.96 +0.7%	$23.33 +112.9%	+48.6%	$647.96M	$106.47M	5.51	20	News Coverage Analyst Forecast Options Volume
CRMD CorMedix	3.3633 of 5 stars	$8.23 +0.7%	$15.00 +82.3%	-39.7%	$645.66M	$400.05M	3.86	30
CADL Candel Therapeutics	2.9341 of 5 stars	$8.80 +4.5%	$18.00 +104.6%	+48.0%	$644.56M	N/A	N/A	60
ACRS Aclaris Therapeutics	3.336 of 5 stars	$4.42 -4.5%	$11.50 +160.2%	+188.6%	$617.30M	$7.83M	N/A	100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MOLN) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Molecular Partners (MOLN) Competitors

MOLN vs. ZVRA, CRMD, CADL, ACRS, and CLYM

How does Molecular Partners compare to Zevra Therapeutics?

Summary

How does Molecular Partners compare to CorMedix?

Summary

How does Molecular Partners compare to Candel Therapeutics?

Summary

How does Molecular Partners compare to Aclaris Therapeutics?

Summary

How does Molecular Partners compare to Climb Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOLN vs. The Competition

Molecular Partners Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Molecular Partners (MOLN) Competitors

MOLN vs. ZVRA, CRMD, CADL, ACRS, and CLYM

How does Molecular Partners compare to Zevra Therapeutics?

Which has better earnings and valuation, ZVRA or MOLN?

Is ZVRA or MOLN more profitable?

Do analysts recommend ZVRA or MOLN?

Do insiders and institutionals have more ownership in ZVRA or MOLN?

Does the media favor ZVRA or MOLN?

Which has more volatility and risk, ZVRA or MOLN?

Summary

How does Molecular Partners compare to CorMedix?

Which has preferable valuation and earnings, CRMD or MOLN?

Which has more risk & volatility, CRMD or MOLN?

Do analysts recommend CRMD or MOLN?

Do institutionals & insiders hold more shares of CRMD or MOLN?

Is CRMD or MOLN more profitable?

Does the media favor CRMD or MOLN?

Summary

How does Molecular Partners compare to Candel Therapeutics?

Which has better earnings and valuation, MOLN or CADL?

Which has more volatility & risk, MOLN or CADL?

Do analysts recommend MOLN or CADL?

Do insiders & institutionals have more ownership in MOLN or CADL?

Is MOLN or CADL more profitable?

Does the media prefer MOLN or CADL?

Summary

How does Molecular Partners compare to Aclaris Therapeutics?

Is ACRS or MOLN more profitable?

Does the media favor ACRS or MOLN?

Which has better valuation & earnings, ACRS or MOLN?

Do analysts prefer ACRS or MOLN?

Do insiders and institutionals hold more shares of ACRS or MOLN?

Which has more volatility and risk, ACRS or MOLN?

Summary

How does Molecular Partners compare to Climb Bio?

Do insiders & institutionals have more ownership in CLYM or MOLN?

Do analysts rate CLYM or MOLN?

Is CLYM or MOLN more profitable?

Which has more volatility and risk, CLYM or MOLN?

Does the media favor CLYM or MOLN?

Which has better earnings & valuation, CLYM or MOLN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOLN vs. The Competition

Molecular Partners Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools